Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

Published Date: 08 Oct 2024

High overall response rate, even though many were ineligible for trial leading to drug's approval

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For relapsed or resistant DLBCL, odronextamab produced positive results.

2.

Prostate cancer screening program beneficial in top decile of polygenic risk score

3.

There has been a new target found that might stop blood cancer.

4.

Prostate cancer explained: From antigen tests to treatment options

5.

A new FDA boxed warning; suicides rocking college campuses; more people getting flu shots than COVID vaccines.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot